Adjuvant Tx HER2 Negative EBC
Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Released: August 22, 2024

Expiration: August 21, 2025

Laura Huppert
Laura Huppert, MD
Kevin Kalinsky
Kevin Kalinsky, MD, MS
Reshma Mahtani
Reshma Mahtani, DO
Laura M. Spring
Laura M. Spring, MD
Tiffany A Traina
Tiffany A Traina, MD, FASCO

Introduction

Get recommendations from 5 experts on individualizing adjuvant therapy for your specific patient with HER2-negative early breast cancer using this Interactive Decision Support Tool.

Interactive Decision Support Tool

Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool

Disclaimer

Access to and use of this Interactive Decision Support Tool titled, “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal adjuvant therapy choices for treating individuals with HER2-negative early breast cancer who have already undergone surgery and, if applicable, are already receiving adjuvant endocrine therapy. The information provided is based on the expert guidance of Kevin Kalinsky, MD, MS; Laura A. Huppert, MD; Reshma L. Mahtani, DO; Laura M. Spring, MD; and Tiffany A. Traina, MD, FASCO.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Adjuvant Therapy for HER2-Negative Early Breast Cancer: Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content